Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lymphangitis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    27 result(s) found for: Lymphangitis. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2009-018014-20 Sponsor Protocol Number: COSAKV1 Start Date*: 2010-04-19
    Sponsor Name:Common Services Agency
    Full Title: A Randomised Phase II Study Evaluating Cediranib vs. Cediranib and Saracatanib in patients with relapsed metastatic clear cell renal cancer
    Medical condition: Clear Cell Renal Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-003340-30 Sponsor Protocol Number: GM307 Start Date*: 2008-08-21
    Sponsor Name:Genta Incorporated
    Full Title: A multicenter, randomized, double-blind study of dacarbazine with or without Genasense in chemotherapy naïve subjects with advanced melanoma and low LDH (The AGENDA Trial)
    Medical condition: Advanced Melanoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027480 Metastatic malignant melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Ongoing) DE (Completed) CZ (Completed) ES (Ongoing) AT (Completed) IT (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-007803-10 Sponsor Protocol Number: 3144A2-3005 Start Date*: 2009-08-26
    Sponsor Name:Puma Biotechnology, Inc
    Full Title: A Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer
    Medical condition: ErbB2 Positive Locally Recurrent or Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) DE (Completed) IT (Completed) GB (Completed) ES (Completed) BE (Completed) LV (Completed) PT (Completed) LT (Completed) FR (Completed) GR (Completed) DK (Completed) MT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-005425-11 Sponsor Protocol Number: 3144A2-3003/B1891003 Start Date*: 2009-01-14
    Sponsor Name:Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA
    Full Title: A Phase 2 Randomized Open Label Study of Neratinib versus Lapatinib plus Capecitabine for the Treatment of ErbB-2 Positive Locally Advanced or Metastatic Breast Cancer
    Medical condition: Locally advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) SI (Completed) BE (Completed) DE (Completed) ES (Completed) CZ (Completed) IT (Prematurely Ended) GR (Completed) FR (Completed) AT (Completed) GB (Completed) BG (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-002301-23 Sponsor Protocol Number: BAP00414 Start Date*: 2005-12-14
    Sponsor Name:Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
    Full Title: A Phase 3, Randomized, Double-Blind Study Of Ceftobiprole Medocaril Versus Vancomycin With Ceftazidime in The Treatment Of Complicated Skin And Skin Structure Infections
    Medical condition: complicated skin and skin structure infection
    Disease: Version SOC Term Classification Code Term Level
    5.1 10040786 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LV (Completed) LT (Completed) EE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2004-001662-41 Sponsor Protocol Number: BAP00154 Start Date*: 2004-09-16
    Sponsor Name:Basilea Pharmaceutica Ltd
    Full Title: A Phase III, Randomized, Double-Blind Study of Ceftobiprole versus Vancomycin in the Treatment of Complicated Skin and Skin Structure Infections
    Medical condition: Complicated skin and skin structure infections
    Disease: Version SOC Term Classification Code Term Level
    LLT 10024768 code
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) LV (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002239-29 Sponsor Protocol Number: WI18274 Start Date*: 2006-03-06
    Sponsor Name:F. Hoffmann - La Roche AG
    Full Title: A phase II prospective, open label, randomized, active-controlled, parallel group, multi-center ‘proof of concept’ trial in adult patients with complicated skin and skin structure infections requir...
    Medical condition: Treatment of adult patients with complicated skin and skin structure infections requiring hospitalization.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) EE (Completed) DE (Completed) LV (Completed) HU (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2004-001149-14 Sponsor Protocol Number: A6181034 Start Date*: 2004-09-27
    Sponsor Name:PFIZER
    Full Title: A Phase 3, Randomized Study of SU011248 versus Interferon-a as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma.
    Medical condition: metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10050513 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-002874-30 Sponsor Protocol Number: 008424QM Start Date*: 2012-12-10
    Sponsor Name:Queen Mary University of London
    Full Title: AN OPEN LABEL RANDOMISED PHASE II STUDY COMPARING AZD2014 VERSUS EVEROLIMUS IN PATIENTS WITH ADVANCED METASTATIC RENAL CANCER AND PROGRESSION ON VEGF TARGETED THERAPY
    Medical condition: Metastatic Clear Cell Renal Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050018 Renal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003847-66 Sponsor Protocol Number: H6Q-MC-S061 Start Date*: 2008-03-28
    Sponsor Name:Eli Lilly and company
    Full Title: Dose Finding and Randomized, Multicenter, Placebo-Controlled, Phase 2 Study of Enzastaurin and Sunitinib versus Placebo and Sunitinib in Patients with Metastatic Renal Cell Carcinoma
    Medical condition: Renal cell carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) AT (Completed) PL (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-000320-14 Sponsor Protocol Number: D6997L00002 (9238SW0001) Start Date*: 2006-03-29
    Sponsor Name:AstraZeneca oy
    Full Title: Anastrozole monotherapy versus maximal oestrogen blockage with anastrozole and fulvestrant comination therapy: An open, randomised, comparative, phase III multicentre study in postmenopausal women ...
    Medical condition: Hormone receptor positive breast cancer in first relapse after primary treatment of localised tumour, in postmenopausal women.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FI (Completed) PT (Completed) IS (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018585-23 Sponsor Protocol Number: A4061051 Start Date*: 2010-12-21
    Sponsor Name:Pfizer Inc 235 East 42nd Street, New York, NY10017
    Full Title: AG-013736 (axitinib) for the treatment of metastatic renal cell cancer (mRCC)
    Medical condition: metastatic renal cell cancer
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-001451-21 Sponsor Protocol Number: A4061032 Start Date*: 2008-06-18
    Sponsor Name:Pfizer Inc.,235 East 42nd Street,New York,NY 10017
    Full Title: AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
    Medical condition: Renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) AT (Completed) FR (Completed) GB (Completed) IE (Completed) DE (Completed) IT (Completed) PL (Completed) GR (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2012-001767-71 Sponsor Protocol Number: RX-3341-302 Start Date*: 2013-06-20
    Sponsor Name:Melinta Therapeutics, Inc
    Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DELAFLOXACIN COMPARED WITH VANCOMYCIN + AZTREONAM IN PATIENTS WITH ACUTE BACTERIAL S...
    Medical condition: ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10052891 Skin bacterial infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LV (Completed) ES (Completed) BG (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2013-003644-23 Sponsor Protocol Number: PTK0796-ABSI-1108 Start Date*: 2015-07-02
    Sponsor Name:Paratek Pharma LLC
    Full Title: A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Linezolid IV/PO for Treating Adult Subjects with Acute Bacterial Skin and Skin Str...
    Medical condition: Acute Bacterial Skin and Skin Structure Infection
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10040872 Skin infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) ES (Completed) PL (Completed) GR (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2013-001352-34 Sponsor Protocol Number: B3271002 Start Date*: 2013-12-18
    Sponsor Name:Pfizer Inc,
    Full Title: A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280014 PLUS PACLITAXEL VERSUS TRASTUZUMAB PLUS PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER
    Medical condition: Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) HU (Completed) ES (Completed) PT (Completed) PL (Completed) GR (Completed) LV (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2015-002669-45 Sponsor Protocol Number: ICL-23-ABSSSI1 Start Date*: 2016-02-18
    Sponsor Name:Motif BioSciences Inc.
    Full Title: A Phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous iclaprim versus vancomycin in the treatment of acute bacterial skin and skin structure infe...
    Medical condition: Acute bacterial skin and skin structure infections (ABSSSIs) suspected or confirmed to be due to Gram-positive pathogens.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10040872 Skin infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) DE (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-014796-51 Sponsor Protocol Number: 120BC201 Start Date*: 2010-02-02
    Sponsor Name:Biogen Idec Ltd.
    Full Title: Phase 2a, open-label, randomized, noncomparative study of BIIB021 in combination with exemestane in women with hormone receptor-positive, advanced metatatic breast cancer who have progressed on a n...
    Medical condition: Advanced Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001467-22 Sponsor Protocol Number: A6181040 Start Date*: 2004-10-26
    Sponsor Name:Pfizer S.A.
    Full Title: A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER
    Medical condition: Histologically proven NSCLC (Stage IV or recurrent disease or locally advanced [Stage IIIB]) that is not amenable to surgery, radiation, or combined modality therapy with curative intent
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002687-16 Sponsor Protocol Number: ICL-24-ABSSSI2 Start Date*: 2016-05-05
    Sponsor Name:Motif BioSciences Inc.
    Full Title: A Phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous iclaprim versus vancomycin in the treatment of acute bacterial skin and skin structure infe...
    Medical condition: Acute bacterial skin and skin structure infections (ABSSSIs) suspected or confirmed to be due to Gram-positive pathogens.
    Disease: Version SOC Term Classification Code Term Level
    19.1 10021881 - Infections and infestations 10040872 Skin infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) HU (Completed) PT (Completed) HR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:47:45 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA